The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 2

Conditions

Arthritis, Rheumatoid

Treatments

Drug: rosiglitazone XR

Study type

Interventional

Funder types

Industry

Identifiers

NCT00379600

ARA102198

Details and patient eligibility

About

To assess whether the anti-inflammatory effects of rosiglitazone result in improvements in Rheumatoid Arthritis symptoms in patients for whom their existing Disease Modifying Anti-Rheumatic Drug (DMARD) treatment does not give adequate relief.

Enrollment

96 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Rheumatoid Arthritis insufficiently controlled by existing disease-modifying anti-rheumatic drugs
Subjects will have at least 6 swollen joints plus 2 of the following: 6 tender joints (of 28 joints); early morning stiffness lasting more than 30 minutes; ESR greater or equal to 28mm/h
must be receiving a stable dose of disease-modifying anti-rheumatic therapy for at least 2 months prior to participating in the study.

Exclusion criteria

Women who are lactating, pregnant, or planning to become pregnant during the course of the study including 30 days following conclusion of study medication
Systolic blood pressure (SBP) >165 mmHg or diastolic blood pressure (DBP) >95 mmHg while receiving optimal antihypertensive therapy
Any clinically significant abnormality identified on the screening physical exam, laboratory tests, or ECG, which in the judgement of the Investigator makes the subject unsuitable for inclusion in the study
a history of alcohol abuse within the past 3 years or consumes >3 units per day for males and >2 units per day for females or has a history of cirrhosis or stigmata of chronic liver disease
a history of liver disease or has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2.5 times upper limit of normal and total bilirubin levels greater than 1.5 times the upper limit of normal (unless associated with predominantly indirect bilirubin or Gilbert's syndrome) at screening
using glucocorticoid at doses >10 mg/day currently or within the last 3 months or may be expected to do so during the course of the study
The subject's dose of NSAIDs, COX-2 inhibitors or glucocorticoids has changed at any time during the past 2 weeks prior to screening or may be expected to change during the course of the study
The subject's dose or treatment with a statin has changed at any time during the past 3 months prior to screening or may be expected to change during the course of the study
a history of renal disease or has serum creatinine = 132mol/L for males and =130mol for females
has diabetes mellitus that requires medication or hyperglycaemia with a HbA1c of >7%
History of new cardiovascular event within the last 6 months (i.e., intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina) or significant arrhythmia; or major intervention (e.g., cardiac surgery or angiography plus stenting) scheduled
Concurrent or past medical history of congestive heart failure or pulmonary oedema
A presence of severe peripheral oedema or a medically serious fluid-related event
has significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or immunological conditions that, in the opinion of the Investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial
a history of malignancy in the last 5 years, except for surgically cured basal cell carcinoma (>2 years prior to first dosing)
a history of HIV, or chronic hepatitis B or positive C serology
a history of drug abuse
has participated in a clinical trial within the 3 months before the start of the study for non-biological therapy; or within 6 months of a biological therapy
on a biological therapy or has received biological therapy within 6 months prior to screening
has donated blood in excess of 500 mL within 56 days prior to dosing
The subject is at risk of non-compliance in following directions or adhering to study restrictions
a history of drug or other allergy, which, in the opinion of the physician responsible, contraindicates their participation
has anaemia defined by haemoglobin concentration <11 g/dL for males or <10 g/dL for females